



A


PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/644,588 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 3 | Attorney Docket Number | 05432/100M919-US3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| 2 | 1. | US-6,469,064 B2 | 10-22-2002 | Druzgala | |
| | 2. | US-6,333,357 B1 | 12-25-2001 | Eig | |
| | 3. | US-6,159,971 | 12-12-2000 | Berg et al. | |
| | 4. | US-6,147,072 | 11-14-2000 | Bymaster et al. | |
| | 5. | US-6,069,177 | 05-30-2000 | Carlier et al. | |
| | 6. | US-5,962,514 | 10-05-1999 | Evenden et al. | |
| | 7. | US-5,958,429 | 09-28-1999 | Wong | |
| | 8. | US-5,788,986 | 08-04-1998 | Dodman | |
| | 9. | US-5,648,396 | 07-15-1997 | Young et al. | |
| | 10. | US-5,296,507 | 03-22-1994 | Tanaka et al. | |
| | 11. | US-5,114,976 | 05-19-1992 | Norden | |
| | 12. | US-4,962,128 | 10-09-1990 | Doogen et al. | |
| | 13. | US-4,943,590 | 07-24-1990 | Boegesoe et al. | |
| | 14. | US-4,902,710 | 02-20-1990 | Foster et al. | |
| | 15. | US-4,650,884 | 01-23-1979 | Bogeso et al. | |
| | 16. | US-4,136,193 | 01-23-1979 | Bogeso et al. | |
| | 17. | US-3,467,675 | 09-16-1969 | Peterson et al. | |
| | 18. | US-Re. 34712 | 08-30-1994 | Boegesoe et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | |
| al | 19. | EP-0 347 066 A1 / | 12-20-1989 | H. Lundbeck A/S | |
| | 20. | WO-01/03694 A1 / | 01-18-2001 | H. Lundbeck A/S | |
| | 21. | WO-00/15220 / | 03-23-2000 | Astra Aktiebolag | |
| | 22. | WO-01/54681 A2 / | 08-02-2001 | Massachusetts Institute of Technology | |
| | 23. | WO-00/15219 / | 03-23-2000 | Astra Aktiebolag | |
| | 24. | WO-00/03701 / | 01-27-2000 | Massachusetts Institute of Technology | |
| | 25. | WO-00/02551 / | 01-20-2000 | NPS Pharmaceutical, Inc. | |
| | 26. | EP-0759299 / | 02-26-1997 | Eli Lilly and Company | |
| | 27. | EP-0714663 A2 / | 06-05-1996 | Eli Lilly and Company | |
| | 28. | WO-93/09769 / | 05-27-1993 | Sepracor, Inc. | |
| | 29. | WO-92/18005 / | 10-29-1992 | National Institutes of Health | |
| | 30. | WO-00/34263 / | 06-15-2000 | H. Lundbeck A/S | |
| | 31. | EP-0474580 / | 03-11-1992 | H. Lundbeck A/S | |

| | | | |
|------------------|---------------|--------------------|---------|
| W:1054 321100 | <i>Ray Ls</i> | Date Considered | 5/14/06 |
|------------------|---------------|--------------------|---------|



B

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/644,588 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 3 | Attorney Docket Number | 05432/100M919-US3 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ² |
| REL | 32. | Kornstein, S.C. and Schneider, R.K., Clinical features of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 18-25 | | | / |
| | 33. | Nierenberg, A.A and DeCecco, L.M., Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: A focus on treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 5-9 | | | / |
| | 34. | Sackeim, H.A., The definition and meaning of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 10-17 | | | / |
| | 35. | Willner, P., Psychopharmacology, 1997, 134, 319-329 | | | / |
| | 36. | A.F. Joubert et al., "Citalopram and Anxiety Disorders," Rev. Contemp. Pharmacother 10: 79-131 (1999) | | | / |
| | 37. | Ulla M. Lepola et al., "A Controlled Perspective, 1 -Year Trial of Citalopram in the Treatment of Panic Disorder," J. Clin. Psychiatry 59, 10: 528-534 (1998) | | | / |
| | 38. | H. Koponen et al., "Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study," Acta Psychiatrica Scandinavica 96:343-346 (1997) | | | / |
| | 39. | Dan J. Stein et al., "Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder," Journal of Serotonin Research 1: 29-33 (1996) | | | / |
| | 40. | Bigler, Allan et al., "Quantitative Structure-activity Relationships in a Series of Selective 5-HT uptake inhibitors," Eur. J. Med. Chem. 3:289-295 (1997) | | | / |
| | 41. | Soraya Seedat et al., "Open Trial of Citalopram in adults with post-traumatic stress disorder," International Journal of Neuropsychopharmacology 3: 135-140 (2000) | | | / |
| | 42. | Ihoko Muraki et al., "Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat," European Journal of Pharmacology 383:223-229 (1999) | | | / |
| | 43. | Jennifer Y. Tan et al, "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy 19, 6: 675-689 (1999) | | | / |
| | 44. | Mario Amore et al., "Short-term and Long-term evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Fluoxetine vs. Citalopram," Hum. Psychopharmacol. Clin. Exp. 14: 435-440 (1999) | | | / |
| | 45. | Emanuela Mundo, M.D. et al., "Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study," Journal of Clinical Psychopharmacology 17, 4: 267-271 (August 1997) | | | / |
| | 46. | Zoltan Rihmer, "Successful treatment of salbutamol-induced panic disorder with citalopram," European Neuropsychopharmacology 7:241-242 (1997) | | | / |
| AL | 47. | Takeshi Inoue et al., "Effect of italopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing," European Journal of Pharmacology 311: 1-6 (1996) | | | / |

| | | | |
|------------------|--|-----------------|---------|
| W:1054 321100 | | Date Considered | 5/14/06 |
|------------------|--|-----------------|---------|



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/644,588 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 3 | of | 3 | Attorney Docket Number | 05432/100M919-US3 |

| | | |
|-----|---|--|
| 48. | U. Lepola et al., "Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia," Pharmacopsychiatry 29: 30-32 (January 1996) | |
| 49. | J. Hyttel et al., "The Pharmacology of Citalopram," Rev. Contemp. Pharmacother. 6: 271-285 (1995) | |
| 50. | American Psychiatric Associations, "DSM-IV" (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994) | |
| 51. | Hyttel, J., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 1982, 6, 277-295 | |
| 52. | Gravem, A., Acta Psychiatr. Scand., 1987, 75, 478-486 | |
| 53. | Sanchez, C., Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats, Behav. Pharmacol. 1993; 4:267-277 | |
| 54. | Sanchez, C., Pharmacol. Toxicol. 77, 71-78 (1995) | |
| 55. | Sanchez, C., R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model, European Journal of Pharmacology, 464, 2003, pp.155-158 | |
| 56. | Montgomery, S. et al., Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model, Pharmacology & Toxicology, 2001, 88, 282-286 | |
| 57. | Sanchez, C., Stress-induced vocalisation in adult animals: A valid model of anxiety?, European Journal of Pharmacology, 463 (2003) 133-143 | |
| 58. | Burke, W., et al., Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients, J. Clin Psychiatry, 63:4, April 2002 | |
| 59. | Wade, A., et al., Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care, International Clinical Psychopharmacology 2002, Vol. 17 No. 3 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|-----------------------|--------------------|---------|
| (W:1054 321100) | <i>By [Signature]</i> | Date Considered | 5/14/08 |
|--------------------|-----------------------|--------------------|---------|



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------------|------------------------|-------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | |
| | | Application Number | 10/644,588-Conf. #5265 | | |
| | | Filing Date | August 20, 2003 | | |
| | | First Named Inventor | Connie Sanchez | | |
| | | Art Unit | 1614 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 1 | of | 2 | Attorney Docket Number | 05432/100M919-US3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| ae | AA* | US-2002/0103249-A1 | 08-01-2002 | H. Lundbeck A/S | |
| | AB* | US-6,184,219-B1 | 02/2001 | Evenden et al. | |
| | AC* | US-6,169,105-B1 | 01/2001 | Wong et al. | |

** Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ae | 1 | Kasper, Siegfried, et al., "Escitalopram is Efficacious and well Tolerated in Treatment of Social Anxiety Disorder", ADA National Conference, 21-24 March 2002, 1 page. | |
| | 2 | Stahl, Stephen, et al., "Escitalopram in the Treatment of Panic Disorder", Presented at the 22nd National Conference of the Anxiety Disorders Association of America, March 21-24, 2002, Austin, Texas, NR56, 1 page. | |
| | 3 | Huffman, Jeff C., et al., "The Development of New Antidepressants: Focus on Duloxetine and Escitalopram", Harv Rev Psychiatry, 11:30-36 (2003). | |
| | 4 | Burke, William J., "Escitalopram", Expert Opin. Investig. Drugs, 11(10): 1477-1486 (2002). | |
| | 5 | Farah, Andrew, "Therapeutic Advantages of Escitalopram in Depression and Anxiety Disorders", Primary Psychiatry, 9(12): 30-35 (2002). | |
| | 6 | Waugh, John, et al., "Escitalopram, A review of its Use in the Management of Major Depressive and Anxiety Disorders", CNS Drugs, 17 (5): 343-362 (2003). | |
| | 7 | Lader, Malcolm, et al., "Efficacy and Tolerability of Escitalopram in 12- and 24-Week Treatment of Social Anxiety Disorder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study", Depression and Anxiety, 19: 241-248 (2004). | |
| | 8 | Davidson, Jonathan, et al., "Escitalopram in the Treatment of Generalized Anxiety Disorder", Presented at the 22nd National Conference of the Anxiety Disorder Association of America, March 21-24, 2002, Austin, Texas, NR57, 1 page. | |
| | 9 | Poster, "Escitalopram and Paroxetine in Fixed Doses for the Treatment of Social Anxiety Disorder (SAD), Presented at the 44th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology, 9-12 April 2003, Juan-les-Pins, France, 1 page. | |
| | 10 | Stahl, et al., J. Clin. Psychiatry 2003; 64: 1322-1327. | |
| | 11 | Montgomery, S.A., et al., "The antidepressant efficacy of citalopram", International Clinical Psychopharmacology (1996), Vol. 11, Supplement 1, pp. 29-33. | |

| | | | |
|-----------------------|--|--------------------|----------|
| Examiner Signature | | Date Considered | 5/1-1/06 |
|-----------------------|--|--------------------|----------|



D

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/644,588-Conf. #5265 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| | | | | Attorney Docket Number | 05432/100M919-US3 |
| Sheet | 2 | of | 2 | | |

| | | | |
|--|----|---|--|
| | 12 | Bouchard, J.M., et al., "Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial", Journal of Affective Disorders, Vol. 46, pp. 51-58 (1997). | |
| | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 5/14/06 |
|-----------------------|--|--------------------|---------|



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------------|------------------------|-------------------|
| Substitute for form 1449A/B/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/644,588-Conf. #5265 | | |
| | | Filing Date | August 20, 2003 | | |
| | | First Named Inventor | Connie Sanchez | | |
| | | Art Unit | N/A | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 1 | of | 2 | Attorney Docket Number | 05432/100M919-US3 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------------------|---|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (# known) | | | | |
| AL | AA** | US-2002/0040153-A1 | | 04-04-2003 | Petersen | |
| | AB** | US-6,258,842-B1 | | 07-10-2001 | Petersen et al. | |
| | AC** | US-6,365,747-B1 | | 02-02-2002 | Dall'Asta et al. | |
| | AD** | US-2004/0132808-A1 | | 07-08-2004 | Petersen et al. | |
| | AE** | US-5,627,196-A | | 05-06-1997 | Hibschman et al. | |

* Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|-----------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
| | | Country Code ³ -Number ¹ -Kind Code ⁵ (if known) | | | | |
| WQ | 1 | WO-01/43525-A2 | 06-21-2001 | Rock et al. | | |
| | 2 | WO-99/14207-A1 | 03-25-1999 | Berg Stefan | | |
| | 3 | WO-0 814 084-A1 | 12-29-1997 | Eli Lilly Co. | | |
| | 4 | WO-96/24353-A1 | 08-15-1996 | Eli Lilly Co. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| AL | 5 | AUQUIER, P., et al., Int. J. Psychiatr. Clin. Pract., 2003, Vol. 7, pp. 259-268. | |
| | 6 | BEIN, E., et al., Behav. Pharmacol., 2003, Vol. 14, p. S37. | |
| | 7 | FISH, E.W., et al., J. Pharmacol. Exp. Ther., October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206, 2004. | |
| | 8 | SANCHEZ, Connie, et al., Psychopharmacology, 2003, Vol. 167, pp. 353-362. | |
| | 9 | SANCHEZ, Connie, et al., Behav. Pharmacol., 2003, Vol. 14, pp. 465-470. | |
| | 10 | SANCHEZ, Connie, et al., "Escitalopram versus citalopram: the surprising role of the R-enantiomer", Psychopharmacology (Berl.), 2004. | |
| | 11 | HYTTEL, J., et al., "The pharmacological effect of citalopram resides in the (S) - (+)-enantiomer", Journal of Neural Transmission, 1992, Vol. 88, No. 2, pp. 157-160. | |
| | 12 | SANCHEZ, Connie, et al., "Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression", Psychopharmacology, 1997, Vol. 129, pp. 197-205. | |
| | 13 | LEPOLA, U., et al., "Citalopram in the Treatment of Social Phobia: A Report of Three Cases", Pharmacopsychiatry, September 1994, Vol. 27, No. 5, pp. 186-188. | |
| | 14 | HUMBLE, M., et al., "Serotonin, Panic Disorder and Agoraphobia: Short-Term and Long-Term Efficacy of Citalopram in Panic Disorders", International Clinical Psychopharmacology, 1992, Vol. 6, No. Suppl. 5, pp. 21-39. | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 5/14/06 |
|-----------------------|--|--------------------|---------|


F

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete If Known | |
| | | | | Application Number | 10/644,588-Conf. #5265 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 2 | Attorney Docket Number | 05432/100M919-US3 |

| | | | |
|----|----|--|--|
| al | 15 | BOUWER, C., et al., "Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia", Journal of Affective Disorders, April 1998, Vol. 49, No. 1, pp. 79-82. | |
| | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner Signature |  | Date Considered | 5/14/06 |
|-----------------------|---|--------------------|---------|



6

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/644,588-Conf. #5265 |
| | | | | Filing Date | August 20, 2003 |
| | | | | First Named Inventor | Connie Sanchez |
| | | | | Art Unit | 1614 |
| | | | | Examiner Name | A. A. Lewis |
| Sheet | 1 | of | 1 | Attorney Docket Number | 05432/100M919-US3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| AA | AA* | US-5,789,449 | 08-04-1998 | Norden | |
| | AB* | US-5,846,982 | 12-08-1998 | Audia et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | | |
| CA | CA | Merck Manual (16th edition, 1992, pg. 1791 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--------------|--------------------|---------|
| Examiner Signature | <i>Ly Lo</i> | Date Considered | 5/14/06 |
|-----------------------|--------------|--------------------|---------|